We say 'congratulations' to our long-term client EsoCap AG for a great success. According to EsoCap, they have reached "Positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis".
Further information on this development you find here.
EsoCap AG is a biotech company placed in Switzerland.
